Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables

Indian Journal of Medical Sciences

Volumn 63, Issue 4, 2009, Pages 152-162

  Mohammadizadeh, Fereshteh ^a   Naimi, Azar ^a   Rajabi, Parvin ^a   Ghasemibasir, Hamidreza ^a   Eftekhari, Amin ^a  

^a ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Basal; Breast cancer; Cytokeratin 5 6; Immunohistochemistry; Luminal

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; CYTOKERATIN 7; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGE DISTRIBUTION; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CLINICAL FEATURE; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PHENOTYPE; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; BREAST NEOPLASMS; CARCINOMA, DUCTAL; FEMALE; GENE EXPRESSION; HUMANS; KERATIN-5; KERATIN-6; KERATIN-7; MIDDLE AGED; PHENOTYPE; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 67650970738     PISSN: 00195359     EISSN: 19983654     Source Type: Journal    
DOI: 10.4103/0019-5359.50764     Document Type: Article

References (27)

1. Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, et al. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol 2006;19:264-271 (Pubitemid 43117611)
2. Fabian CJ, Kimler BF, Elledge RM, Grizzle WE, Beenken SW, Ward JH. Models for early chemoprevention trials in breast cancer. Hematol Oncol Clin North Am 1998;12:993-1017.
3. Laakso M, Loman N, Borg A, Isola J. Cytokeratin 5/14-positive breast cancer: True basal phenotype confined to BRCA1 tumors. Mod Pathol 2005;18:1321-1328 (Pubitemid 41348650)
4. van de Rijn M, Perou CM, Tibshirani R, Haas P, Kallioniemi O, Kononen J, et al. Expression of cytokeratins 17 and 5 identifies a group of breast carcinomas with poor clinical outcome. Am J Pathol 2002;161:1991-1996 (Pubitemid 35434844)
5. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, Pinder SE, et al. 5- Estrogen receptornegative breast carcinomas: A review of morphology and immunophenotypical analysis. Mod Pathol 2005;18:26-35.
6. Wetzels RH, Kuijpers HJ, Lane EB, Leigh IM, Troyanovsky SM, Holland R, et al. Basal cellspecific and hyperproliferation-related keratins in human breast cancer. Am J Pathol 1991;138: 751-763
7. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752
8. Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, et al. Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers. Breast Cancer Res 2007;9:R16. (Pubitemid 350215145)
9. Korsching E, Packeisen J, Agelopoulos K, Eisenacher M, Voss R, Isola J, et al. Cytogenetic alterations and cytokeratin expression patterns in breast cancer: Integrating a new model of breast differentiation into cytogenetic pathways of breast carcinogenesis. Lab Invest 2002;82:1525-1533 (Pubitemid 35332911)
10. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004;10: 5367-5374 (Pubitemid 39100473)
11. Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol 2004;203:661-671 (Pubitemid 38714103)
12. Tischkowitz M, Brunet JS, Bégin LR, Huntsman DG, Cheang MC, Akslen LA, et al. Use of immunohistochemical markers can refine prognosis in triple negative breast cancer. BMC Cancer 2007;7:134. (Pubitemid 47272190)
13. Kesse-Adu R, Shousha S. Myoepithelial markers are expressed in at least 29% of oestrogen receptor negative invasive breast carcinoma. Mod Pathol 2004;17:646-652 (Pubitemid 38715486)
14. Tsuda H, Takarabe T, Hasegawa F, Fukutomi T, Hirohashi S. Large, central acellular zones indicating myoepithelial tumor differentiation in high-grade invasive ductal carcinomas as markers of predisposition to lung and brain metastases. Am J Surg Pathol 2000;24:197-202. (Pubitemid 30078708)
15. Trendell-Smith NJ, Peston D, Shousha S. Adenoid cystic carcinoma of the breast: A tumour commonly devoid of oestrogen receptors and related proteins. Histopathology 1999;35:241-248 (Pubitemid 29468958)
16. Rosen PP, Cranor ML. Secretory carcinoma of the breast. Arch Pathol Lab Med 1991;115:141-144
17. Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, et al. Basal-like breast carcinomas: Clinical outcome and response to chemotherapy. J Clin Pathol 2006;59:729-735 (Pubitemid 44048783)
18. Potemski P, Kusinska R, Watala C, Pluciennik E, Bednarek AK, Kordek R. Prognostic relevance of basal cytokeratin expression in operable breast cancer. Oncology 2005;69:478-485.
19. Laakso M, Tanner M, Nilsson J, Wiklund T, Erikstein B, Kellokumpu-Lehtinen P, et al. Basoluminal carcinoma: A new biologically and prognostically distinct entity between basal and luminal breast cancer. Clin Cancer Res 2006;12:4185-4191
20. Gruvberger SK, Ringnér M, Edén P, Borg A, Fernö M, Peterson C, et al. Expression profiling to predict outcome in breast cancer: The influence of sample selection. Breast Cancer Res 2003;5: 23-26
21. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 2003;100:10393-10398
22. Rakha EA, Putti TC, Abd El-Rehim DM, Paish C, Green AR, Powe DG, et al. Morphological and immunophenotypical analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol 2006;208:495-506.
23. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685
24. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100:8418-8423
25. Birnbaum D, Bertucci F, Ginestier C, Tagett R, Jacquemier J, Charafe-Jauffret E. Basal and luminal breast cancers: Basic or luminous? Int J Oncol 2004;25:249-258
26. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006;295:2492-2502
27. Rodriguez-Pinilla SM, Sarrió D, Honrado E, Hardisson D, Calero F, Benitez J, et al. Prognostic significance of basal-like phenotype and fascin expression in node-negative invasive breast carcinomas. Clin Cancer Res 2006;12:1533-1539